The Inflation Reduction Act’s policy capping out-of-pocket costs for insulin to $35 for a month’s supply led to increases in the total number of insulin fills for Medicare beneficiaries, according to a new study from the USC Schaeffer Center for Health Policy & Economics and University of Wisconsin–Madison.
Exclusive: Pfizer to invest $25M into tiny UK biotech with epigenetics approach to cancer
Cambridge, UK-based startup CellCentric is receiving $25 million to finish ongoing clinical studies and get some extra runway in the form of a cash infusion